Your browser is no longer supported. Please, upgrade your browser.
Settings
CUE [NASD]
Cue Biopharma, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own0.80% Shs Outstand30.30M Perf Week3.05%
Market Cap394.75M Forward P/E- EPS next Y-1.66 Insider Trans-9.05% Shs Float27.02M Perf Month-8.61%
Income-44.80M PEG- EPS next Q-0.38 Inst Own64.60% Short Float11.61% Perf Quarter-10.95%
Sales3.20M P/S123.36 EPS this Y6.20% Inst Trans0.19% Short Ratio10.01 Perf Half Y-16.18%
Book/sh2.60 P/B4.94 EPS next Y-9.90% ROA-48.70% Target Price- Perf Year-40.23%
Cash/sh2.76 P/C4.65 EPS next 5Y- ROE-61.40% 52W Range10.75 - 31.69 Perf YTD2.72%
Dividend- P/FCF- EPS past 5Y-68.20% ROI-57.30% 52W High-59.45% Beta-
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low19.53% ATR0.88
Employees50 Current Ratio5.40 Sales Q/Q-50.00% Oper. Margin- RSI (14)51.34 Volatility6.06% 6.61%
OptionableYes Debt/Eq0.00 EPS Q/Q0.70% Profit Margin- Rel Volume0.65 Prev Close12.35
ShortableYes LT Debt/Eq0.00 EarningsMar 16 AMC Payout- Avg Volume313.37K Price12.85
Recom1.30 SMA205.12% SMA50-4.26% SMA200-15.27% Volume202,294 Change4.05%
Nov-24-20Initiated Berenberg Buy $30
Apr-09-20Initiated Stifel Buy $21
Jan-28-20Initiated BTIG Research Buy $26
Jan-22-20Initiated JMP Securities Mkt Outperform $22
Apr-09-21 02:14AM  
Mar-16-21 04:01PM  
Mar-15-21 08:00AM  
Mar-09-21 08:00AM  
Mar-01-21 08:00AM  
Feb-25-21 08:00AM  
Feb-23-21 12:17AM  
Feb-22-21 08:00AM  
Feb-17-21 08:00AM  
Feb-08-21 08:00AM  
Jan-29-21 03:34PM  
Jan-09-21 02:27AM  
Dec-15-20 10:30PM  
Dec-07-20 08:53AM  
Nov-25-20 12:02AM  
Nov-24-20 09:51AM  
Nov-23-20 08:00AM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 08:00AM  
Nov-03-20 06:25AM  
Oct-19-20 08:00AM  
Oct-14-20 11:30AM  
Sep-17-20 08:00AM  
Sep-15-20 08:00AM  
Sep-10-20 08:36AM  
Sep-04-20 10:07AM  
Sep-03-20 08:00AM  
Aug-31-20 04:01PM  
Aug-24-20 08:00AM  
Aug-17-20 08:00AM  
Aug-06-20 12:30PM  
Jul-28-20 08:00AM  
Jul-08-20 08:00AM  
Jul-06-20 02:36PM  
Jun-27-20 09:12PM  
Jun-15-20 08:00AM  
May-28-20 08:00AM  
May-20-20 09:01PM  
May-19-20 10:00PM  
04:01PM  
May-18-20 08:00AM  
May-14-20 08:00AM  
May-12-20 08:00AM  
May-06-20 12:30PM  
Apr-27-20 10:02AM  
Apr-24-20 11:07AM  
10:50AM  
Apr-23-20 07:25AM  
Apr-20-20 08:00AM  
Mar-17-20 04:05PM  
Mar-11-20 08:31AM  
Mar-10-20 08:00AM  
Mar-09-20 10:33AM  
Mar-05-20 12:30PM  
Feb-26-20 08:00AM  
Feb-19-20 08:00AM  
Feb-14-20 09:40AM  
Feb-12-20 08:00AM  
Feb-03-20 03:31AM  
Jan-30-20 10:00AM  
Jan-29-20 08:55AM  
Jan-21-20 08:00AM  
Jan-14-20 11:13AM  
Jan-13-20 10:17AM  
10:14AM  
Jan-07-20 07:20AM  
Jan-03-20 08:22AM  
Jan-02-20 10:19AM  
Jan-01-20 12:00PM  
Dec-20-19 05:03PM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-06-19 12:00PM  
Dec-02-19 09:02AM  
08:00AM  
Nov-15-19 09:00AM  
Nov-12-19 04:00PM  
Nov-06-19 08:00AM  
Nov-05-19 08:00AM  
Nov-03-19 08:32AM  
Oct-30-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 04:30PM  
08:00AM  
Oct-07-19 04:30PM  
Oct-02-19 08:00AM  
Sep-30-19 08:00AM  
Sep-19-19 10:48AM  
Jul-12-19 12:34PM  
Jun-03-19 08:00AM  
May-16-19 08:15AM  
08:00AM  
May-09-19 08:00AM  
Apr-29-19 10:07AM  
Apr-08-19 08:00AM  
Mar-14-19 08:00AM  
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pienta KennethChief Medical OfficerMar 16Option Exercise5.004392,1952,439Mar 17 04:00 PM
Pienta KennethChief Medical OfficerMar 16Sale15.094396,6262,000Mar 17 04:00 PM
Pienta KennethChief Medical OfficerMar 15Option Exercise5.0013,00065,00015,000Mar 17 04:00 PM
Pienta KennethChief Medical OfficerMar 15Sale15.1013,000196,2692,000Mar 17 04:00 PM
Pienta KennethChief Medical OfficerFeb 17Option Exercise4.364,27418,6316,274Feb 18 08:44 PM
Pienta KennethChief Medical OfficerFeb 17Sale15.054,27464,3452,000Feb 18 08:44 PM
Pienta KennethChief Medical OfficerFeb 16Option Exercise2.8616,00045,76018,000Feb 18 08:44 PM
Pienta KennethChief Medical OfficerFeb 16Sale15.1516,000242,4222,000Feb 18 08:44 PM
Pienta KennethChief Medical OfficerJan 20Buy15.072,72040,9804,720Jan 22 04:33 PM
Fletcher Aaron G.L.DirectorNov 24Buy12.646,54882,776165,000Nov 25 04:09 PM
Gray CameronDirectorSep 30Buy15.305,00076,500677,500Oct 01 04:13 PM
Gray CameronDirectorSep 29Buy15.005,00075,000672,500Oct 01 04:13 PM
Millar Kerri-AnnCFOAug 21Option Exercise0.006,66607,666Aug 25 04:12 PM
Suri AnishPresident and CSOAug 05Option Exercise6.428005,13635,358Aug 07 05:41 PM
Sandercock ColinSVP, General Counsel and SecAug 05Option Exercise7.5013,27499,55530,399Aug 07 05:44 PM
Sandercock ColinSVP, General Counsel and SecAug 05Sale20.0013,274265,48017,125Aug 07 05:44 PM
Suri AnishPresident and CSOAug 05Sale20.0180016,00834,558Aug 07 05:41 PM
Suri AnishPresident and CSOAug 04Option Exercise6.424002,56834,958Aug 05 04:50 PM
Sandercock ColinSVP, General Counsel and SecAug 04Option Exercise7.502011,50817,326Aug 05 04:51 PM
Suri AnishPresident and CSOAug 04Sale20.144008,05634,558Aug 05 04:50 PM
Sandercock ColinSVP, General Counsel and SecAug 04Sale20.052014,03017,125Aug 05 04:51 PM
Sandercock ColinSVP, General Counsel and SecAug 03Option Exercise7.506,42548,18823,550Aug 05 04:51 PM
Suri AnishPresident and CSOAug 03Option Exercise7.055,80040,91640,358Aug 05 04:50 PM
Sandercock ColinSVP, General Counsel and SecAug 03Sale20.006,425128,50017,125Aug 05 04:51 PM
Suri AnishPresident and CSOAug 03Sale20.015,800116,05834,558Aug 05 04:50 PM
Fletcher Aaron G.L.DirectorJun 24Buy24.887,500186,572158,452Jun 25 04:01 PM